LN-145S1 is under clinical development by Iovance Biotherapeutics and currently in Phase II for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LN-145S1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LN-145-S1 is under development for the treatment of metastatic melanoma, relapsed or refractory soft tissue sarcoma, osteosarcoma, bone sarcoma, anaplastic thyroid cancer, ovarian cancer, head and neck squamous cell carcinoma and non-small cell lung cancer (NSCLC). It is administered by intravenous route. The therapeutic candidate comprises autologous tumor infiltrating lymphocytes (TILs).
Iovance Biotherapeutics overview
Iovance Biotherapeutics (Iovance) is a biotechnology company that focuses on the development and commercialization of novel immunotherapy products for treating various cancers. It develops products based on its tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidates include lifileucel is an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer; and LN-145 for the treatment of head and neck cancer. The company also focuses on investigating TIL therapy for treatment of a range of cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.
For a complete picture of LN-145S1’s drug-specific PTSR and LoA scores, buy the report here.